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Sixteen episodes of cytomegalovirus (CMV) disease occurred in 10 of 41 children undergoing 
intestinal transplantation from 1990 to 1995. Stratification of CMV disease by donor (D)/recipient 
(R)serological status was as follows: 3 ofS, D+/R-; 3 of 9, D+IR+; 4 of9, D-IR+; and 0 of IS, D-I 
R -. Treatment resulted in resolution of CMV disease in 93.3% of episodes. No deaths attributable to 
CMV disease occurred in this series. CMV in D+IR- children resulted in more extensive and 
persistent disease. However, patient and graft survival rates were similar in the different D/R 
subgroups and between children with and without CMV disease. Cumulative dose of steroid boluses 
(relative risk [RR]. 1.59; 95% confidence interval [CI]. 1.14-2.21) and history of steroid recycles 
(RR, 2.72; 95% CI, 1.21-6.13) were associated with CMV disease. These results suggest that although 
CMV -associated morbidity in pediatric intestinal transplant recipients was substantial, it was not 
associated with an increased rate of mortality or graft loss, even among high-risk D+IR - patients. 
Although the intestine was one of the first organs to be 
transplanted experimentally, the clinical evolution of intestinal 
transplantation has remained hindered by technical, immuno-
logic, and infectious complications [1-3]. Recently, with ad-
vances in surgical and clinical management and the use of 
tacrolimus (FK-506) as the principal immunosuppressive drug, 
actuarial patient and graft survivals at 24 months post-trans-
plantation have exceeded 74% and 63%, respectively [4]. Infec-
tions, however, continue to be a significant cause of morbidity. 
We have previously reported high rates of late mortality and 
graft loss due to cytomegalovirus (CMV) infection in our over-
all experience with adult and pediatric intestinal transplant re-
cipients [5]. The occurrence of CMV infection followinE intes-
tinal transplantation in children, however, may have differing 
epidemiological and behavioral characteristics, as has been 
seen with other organ recipients. A retrospective analysis of 
our experience with CMV after intestinal transplantation in 
children is the basis of this report. 
Materials and Methods 
The medical records of children who received either isolated 
small bowel (SB), liver-small bowel (L-SB), or multivisceral 
transplants between 1990 and 1995 at the Children's Hospital 
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of Pittsburgh were systematically reviewed, and data were col-
lected regarding clinical course, virological studies, biopsy re-
sults, immunosuppression, and outcome, with use of standard-
ized definitions. The donor and recipient surgical procedures 
were as previously described [6]. 
fmmunosuppre~sive regimens and graft surveillance. 
Immunosuppressive regimens varied slightly over the study 
period and have been reported elsewhere [7]. All children re-
ceived a combination of tacrolimus and steroids. In addition, 
all but the first eight intestinal graft recipients received prosta-
glandin E I until intravenous tacrolirnus was withdrawn. A low 
dose of azathioprine was added for selected patients, in cases 
of tacrolimus-induced renal toxicity or to enhance baseline 
immunosuppression in cases of recurrent rejection. Suspected 
or proven rejection was initially treated with bolus steroids and 
optimization of tacrolimus levels. A steroid recycle was used 
in cases of more severe rejection or when bolus therapy was 
inadequate. OKT3 was used for steroid refractory rejection. 
Surveillance endoscopy was performed and mucosal biopsies 
were performed twice weekly during the initial transplant ad-
mission and thereafter whenever clinically indicated. The histo-
logic definition of rejection has been described elsewhere [8]. 
Diagnosis of CMV Serological studies for CMV from the 
donor and recipient were performed preoperatively. All patients 
received CMV -negative blood products during the transplanta-
tion operation and throughout their posttransplantation course. 
Blood, urine, and respiratory specimens for CMV cultures were 
obtained as part of the routine evaluation of fever. In addition. 
al! endoscopic specimens were evaluated histologically for the 
presence of CMV, as defined by the presence of inclusions or 
by immunoperoxidase staining. 
Definition of CMV infection. CMV infection was defined 
by (l) the CMV-positivity of a culture specimen from :lny 
site after transplantation or (2) seroconversiol1 in a previOUSly 
seronegative patient. Isolation of CMV was attempted hy shell 
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vial assay [9J and by standard culture. CMY IgG was measured 
by a commercially available assay [10] (FIA,X; Whittaker Bio-
products, Walkersville. MD) 
CMY disease was defined by the presence of symptoms 
attributable to CMY infection in a patient with a positive cul-
ture (of blood. urine. respiratory secretions. or tissue) or histo-
logically positive biopsy tissue (documented by the presence 
of inclusions or by immunofluorescent staining), in the absence 
of another pathogen to explain these symptoms. CMY enteritis 
was diagnosed by histologic evidence of CMY within the gas-
trointestinal tract in association with fever, abdominal bloating, 
and diarrhea or an increase in stool or stomal output. CMY 
hepatitis was diagnosed by the presence of fever, elevated 
transaminase levels, and characteristic histopathology. 
CMY pneumonia was diagnosed when patients had clinical 
and/or radiographic evidence of lower respiratory tract disease 
and a culture-positive bronchoalveolar lavage specimen. Recur-
rence of CMY disease was defined as a new episode of disease 
after at least 1 month of negative his!opathology and/or virol-
ogy. Persistent CMY disease was defined by the continuous 
presence of CMY in serial histologic specimens for> 1 month. 
CMV prophylaxis and treatment. The prophylactic strategy 
against CMY evolved during the study period. Twelve patients 
who underwent transplantation between July 1990 and July 
1992 received prophylaxis with oral acyclovir (800 mg/m2) 
four times a day for 12 weeks after transplantation. Twenty-
nine patients who received transplants between July 1992 and 
July 1995 received intravenous gancic10vir (10 mg/[kg' d], di-
vided into two doses) for the first 2 weeks after transplantation. 
Twenty of the 29 patients subsequently received oral acyclovir 
for the next 10 weeks following intestinal transplantation. 
Three of these 29 were given concomitant CMY-specific hyper-
immunoglobulin (100 mg/[kg' d]) (Cytogam; Medimmune, 
Gaithersburg, MD), according to the previously published pro-
tocol for prevention of CMY disease in adult liver transplant 
recipients [11]. 
Episodes of CMY disease were treated with intravenous gan-
ciclovir alone or in combination with CMY -specific hyperim-
munoglobulin (100 mg/kg, three times per week) until resolu-
tion of clinical symptoms and histologically proven elimination 
of inclusion bodies. For patients with persistent CMY disease, 
CMY -specific hyperimmunoglobulin was administered be-
tween one and four times per month until resolution of CMY 
disease. Immunosuppression was maintained at a therapeutic 
baseline and reduced only when clinical status deteriorated. 
Statistical methods. Incidence and outcome of CMY were 
evaluated for all pediatric intestinai transplantation recipients. Pa-
bent Survival was calculated from the date of transplantation until 
death, and graft survival from the date of transplantation until 
fetransplantation or death. CMY -disease-free survival was calcu-
lated from the date of transplantation until diagnosis of CMY 
, d' 
lsease. Survival curves were generated by the Kaplan-Meier 
method and compared by the log-rank (Mantel-Cox) test. Wil-
COXOn's rank-sum test was used to compare the median number 
of acute allograft rejection episodes between groups. Pearson's X" 
test or Fisher's exact test was used to compare proportions 
Analyses were also perfom1ed according to donor/recipient 
(D/R) serological status (i.e., D-/R-, D+/R-. D-/R+. or 
D+/R+). Cox's proportional hazards model was used to ana-
lyze risk factors for CMY disease, rejection, and mortality. 
Cox's model was used to compute relative risk and 95% confi-
dence intervals. The cumulative dose of steroids and number 
of steroid recycles were incorporated into the Cox's model as 
time-dependent covariates. Also incorporated as time-depen-
dent covariates were the incidences of rejection and CMY dis-
ease. 
Results 
Patient population. During the study period, 41 children 
received 44 intestinal transplants at our center. There were 10 
isolated SB, 27 L-SB, and 7 multivisceral transplants. Five 
patients also received a concomitant donor bone marrow infu-
sion, and 20 received an allograft colon; these latter sets of 
patient~ were distributed among all three recipient cohorts. 
There were 19 males and 22 females with ages ranging between 
0.5 and 18.1 years (mean, 4.2 years). 
CMV infection and disease. The incidence and recurrence 
rate of CMY 'disease, according to Q!R CMY serostatus of the 
patients, are shown in table 1. CMY disease occurred in 10 
(24%) of the 41 children. None of the 15 patients in the 
D-/R- cohort developed CMY infection or disease. In con-
trast,3 of8 D+/R -,3 of9 D+/R +, and 4 of9 D-/R + patients 
developed CMV disease, resulting in a combined incidence for 
these three cohorts of 10 of 26 (38%). CMY disease was ini-
tially seen a median of 53.5 days (range, 9-121 days) post-
transplantation, while the second episode occurred a median 
of 225 days (range, 85-1,350 days) following transplantation. 
The intestinal allograft was affected in 90% of patients who 
developed CMY disease and in 11 (69%) of the 16 episodes 
of CMY disease. The diagnosis of CMY in the intestinal allo-
graft was based on histology in 10 instances and isolation of 
CMY from a gastric biopsy specimen in the remaining epi-
sodes. CMY also invaded the native stomach, duodenum, and 
colon in 20% of children with CMY disease, although this 
occurred only in D+/R- children. 
The distribution of CMY disease by site of involvement was 
as follows: intestinal allograft enteritis (10), allograft gastritis 
(1), native gastroduodenitis (2), native colitis (2), and pneumo-
nitis (3). CMY hepatitis was not seen, even though the liver 
was part of the composite allograft in 73% of these patients. 
The three episodes of pneumonitis were relatively mild and 
did not result in major changes in the clinical status of the 
patients. 
Recurrent CMY disease was observed in 5 of the 10 patients 
with symptomatic CMY: 4 patients had 2 episodes and 1 patient 
had 3 episodes. Three episodes of recurrent CMY disease oc-
curred in the gastrointestinal tract. Of the two remaining recur-
r~: .. 
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Table 1. Incidence, recurrence rate, and outcome of cytomegalovirus disease in pediatric intestinal 
transplant recipients, according to donor/recipient serostatus. 
No. of episodes No. of patients 
Incidence: no. (%) with CMY 
No. of developing CMY CMY Recurrent disease at time 
Serostatus patients disease disease CMY disease of death 
D-/R- 15 0 0 0 0 
D+/R- 8 3 (37) 5 2 0 
D+/R+ 9 3 (33) 4 I I 
D-/R+ 9 4 (44) 7 2 0 
NOTE. CMY = cytomegalovirus; D = donor; R = recipient. 
rences, one consisted of a febrile illness associated with a 
positive buffy coat culture for CMV and the other involved 
the lung. Persistent CMV disease occurred in 2 patients (includ-
ing 1 of the 5 patients with recurrent disease), who were in 
the D+/R- subgroup; resolution of disease occurred for both 
patients after 7 months of therapy. 
Asymptomatic CMV infection occurred in 1 D+/R + and 2 
D-/R+ recipients who had previously had 1 episode each of 
CMV disease. 
Because the cohort of 15 D-/R- intestinal transplantation 
recipients had no CMV infection or disease, subsequent analy-
sis of CMV disease was restricted to the 26 at-risk children who 
either were seropositive pretransplantation or had a seropositive 
donor (D+/R -, D-/R +, or D+/R +). The epis9des of CMV 
disease among the 26 at-risk children were distributed among 
allograft types as follows: SB, 3 of 4; L-SB, 5 of 19; and 
multivisceral, 2 of 3. Although determination of differences in 
the incidence of CMV disease between allograft types is limited 
by the small number of transplant recipients, a trend toward a 
lower incidence ofCMV disease occurred among L-SB recipi-
ents (5 of 19), in comparison with recipients of an isolated SB 
(3 of 4) (P = .103, Fisher's exact test). No relationship was 
found between age, donor sex, or recipient sex and the occur-
rence of CMV disease. 
The incidence of CMV disease in patients receiving gan-
ciclovir prophylaxis was 6 of 19 (33%), vs. 4 of 7 (57%) in 
those receiving only oral acyclovir (P = .547, Fisher's exact 
test). Among children receiving intravenous ganciclovir pro-
phylaxis, the rate of CMV disease was no different in those 
receiving ganciclovir alone than in those treated with gan-
ciclovir followed by oral acyclovir (2 of 5 vs. 2 of 11; P = .547, 
Fisher's exact test). Two patients who received gancic10vir 
and CMV-specific hyperimmunoglobulin (one D+/R- and the 
other D-/R+) developed CMV disease, while a third patient 
(D+/R +) treated with this regimen did not develop symptom-
atic CMV disease. 
Pathology of CMV disease. Histologically, numerolls in-
clusion bodies were usually detected. Although most CMV-
infected cells had characteristic nuclear andlor cytoplasmic 
inclusion bodies, an atypical appearance was noted in some 
patients with CMV disease. This atypical appearance was char-
acterized by the presence of a hyperchromatic smudged nucleus 
that sometimes protruded into the lumen of the gland. In addi-
tion, we noted muscle cells with large hyperchromatic and 
irregular nuclei, as well as endothelial cells with a single large 
or many smaller eosinophilic bodies (figure lA). The use of 
immunoperoxidase stain for CMV was helpful in confirming 
the diagnosis of CMV within these atypical cells. Associated 
inflammatory changes included cryptitis (figure IB) and gland 
damage, sometimes with prominent apoptosis, as well as vari-
able chronic inflammation. 
Outcome of CMV disease. Successful clinical management 
of CMV disease was accomplished in 90% of patients with 
CMV disease and in 93% of episodes. Management typically 
consisted of administration of intravenous ganciclovir alone 
or in combination with CMV-specific hyperimmunoglobulin. 
Baseline immunosuppression was maintained unless there was 
clinical deterioration. Gancic10vir was used for 14-28 days in 
all but the two patients with persistent CMV disease. 
The median time to I'esolution (defined by the absence of 
inclusions in serial gastrointestinal biopsy specimens) after di-
agnosis was 20 days (range, 8 days to 7 months). Three patients 
with a history of CMV disease died. One D + IR + patient died 
of severe intestinal allograft rejection, with evidence of persis-
tent CMV infection at the time of death; two patients (one 
D+IR + and the other D+/R -) died of postransplantation 
lymphoproliferative disease, without evidence of symptomatic 
CMV disease at the time of death. 
The actuarial rates of patient and graft survival were com-
pared between the different D/R CMV serological subgroups 
by the Kaplan-Meier method. No statistically significant differ-
ence was observed in the 2-year patient or graft survival rates 
among the four subgroups or between any pair of serological 
subgroups (D-/R - patient survival, 53%, and graft survival. 
53%; D+/R+, 67% and 67%; D+/R-, 50% and 46%; and 
D-/R +,53% and 53%). Similarly, the 2-year patient survival 
rates were compared between patients with and without CMV 
disease. A survival rate of 61 % was found among patients with 
CMV disease. VS. a 56% survival rate among children without 
CMV disease (P = NS). The 2-year survival rate of each of 
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Figure 1. A. Colonic mucosi\ with numerous cells infected with cytomegalovirus in a pediatric patient following intestinal transplantation. 
The morphology varied from diagnostic inclusions, to cells resembling ganglion cells, to some with dense eosinophilic granules or bodies 
(arrows). B. Cryptitis with large hyperchromatic cell (arrow). Such cells in these patients should always raise the suspicion of viral infection 
(hematoxylin/eosin stain; original magnification, X 400). 
these two groups of children did not· differ from that of the 
D-/R - cohort, which was 57%. 
Interaction of rejection and eMv. One or more episodes 
of rejection occurred in 14 of 16 patients with CMV disease, 
vs. 8 of 10 patients with no history of CMV disease (P = NS). 
The relative risk of developing rejection among patients with 
and without CMV disease was 0.79 (95% cr, 0.15-4.10). Simi-
larly, a history of rejection did not appear to be a risk factor 
for CMV disease (RR; 1.19; 95% cr, 0.30-4.73). However, 
rejection was diagnosed histologically a mean of 4.7 days 
(range, 0-11 days) before the diagnosis of CMV disease in 13 
of 16 (81%) of the CMV disease episodes observed in this 
study. Among the 10 episodes of CMV disease involving the 
intestinal allograft, all were immediately preceded by or oc-
curred concomitantly with an episode of rejection. 
The role of augmented immunosuppression in the incidence 
of CMV disease was also evaluated. The cumulative dose of 
steroid boluses and recycles given was associated with an in-
creased incidence of CMV disease (respectively: RR, 1.59, and 
95% CI, 1.14-2.21; RR, 2.72, and 95% Cl, 1.21-6.13). Five 
patients were receiving azathioprine. The effect of OKT3 on 
the incidence of CMV disease was also explored in the 26 at-
risk patients. Four of nine children receiving OKT3 developed 
CMV disease, compared with six of 17 of these at-risk children 
who did not receive OKT3 (P = NS). 
Discussion 
Infection with CMV has long been recognized as a major 
cause of morbidity and mortality following solid-organ 
transplantation, since the first reports of such infection in 
human transplant recipients [12-16]. Our initial report of 
CMV disease among adult and pediatric intestinal transplant 
recipients identified a high incidence, rate of recurrence, and 
rate of intractability of CMV disease [17], compared with 
those ~f CMV disease in other organ transplant recipients. 
However, in this current report, we identified an incidence 
of CMV disease of 24% among pediatric intestinal transplant 
recipients, which is similar to the i:r:cidence observed among 
children receiving liver allografts [16] and half of what we 
previously observed in our adult intestinal transplant recipi-
ents (46%) [5]. 
This decreased rate in children is likely explained by the 
large number of D-/R - pediatric intestinal transplant recipi-
ents at our center and contrasts with our adult intestinal trans-
plantation experience, in which transplantation among D-/R-
patients has rarely occurred. The overall recurrence rate of 
CMV disease found in this study was 50%, which is similar 
to the rate of recurrence found in adult intestinal transplant 
recipients and is within the range found in recipients of other 
solid organs (6%-59%) [18]. 
CMV involvement of the gastrointestinal tract was fre-
quently noted in this study. This may be explained by a higher 
tropism for CMV in gastrointestinal epithelial cells [19] and 
endothelial cells [20] and by the large number of donor lympho-
cytes, monocytes, and polymorphonuclear leukocytes [21]. The 
intestinal allograft was affected in 90% of our children with 
CMV disease and in 68.7% of the CMV disease episodes. 
Involvement of the native gastrointestinal tract was observed 
only in CMV D+/R- patients. CMV hepatitis was not seen, 
even though the liver was part of the composite allograft in 
nearly 75% of these patients. 
Augmentation of immunosuppression for the treatment of 
rejection may interfere with the host mechanisms against CMV 
infections, specifically by decreasing the number of cytotoxic 
T lymphocytes and natural killer cells [22, 23]. In addition, 
steroid therapy has been associated with CMV inclusions in 
the gastrointestinal tract [24, 25]. Similar to findings in our 
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previous report of adult and pediatric intestinal transplant recip-
ients [5, 17], the cumulative doses of steroid boluses and recy-
cles were associated with a higher incidence of CMV in this 
experience with children. 
Transplant rejection has been suggested as a risk factor for 
the development of CMV disease [26]. However, despite the 
fact that histologic findings suggestive of rejection were found 
shortly before the majority of episodes of CMV disease in our 
patients, rejection was not a risk factor for CMV disease in 
this study (RR, 1.4). The fact that rejection was not identified 
as a risk factor despite being present just prior to >80% of 
episodes of CMV disease may be explained by the relatively 
high frequency of allograft rejections in all of our patients 
during the period of peak risk for CMV disease. Given this 
high frequency of rejection, the relatively small sample size 
available for analysis in this study may not have the power to 
identify differences between children with and without rejec-
tion. 
Finally, the presence of CMV has been suggested to be a 
risk factor for rejection after transplantation [27, 28]. We'were 
not able to show an increased incidence of rejection after CMV 
disease in our patients. 
Management of CMV disease with ganciclovir alone or in 
combination with CMV -specific hyperimmunoglobulin while 
maintaining baseline immunosuppression resulted in resolution 
of >90% of the episodes of CMV disease observed in this 
study. Maintenance of immunosuppression at baseline levels 
prevented the development of rebound rejection and'the subse-
quent need for augmentation of immunosuppressive therapy. 
Although most episodes of CMV disease resolve within 14-
28 days of antiviral therapy, long-term therapy (7 months)"with 
subsequent "weaning" was required in two D+/R - children. 
The use of foscamet in conjunction with ganciclovir might 
provide more potent anti-CMV therapy [29, 30] for patients 
with persistent CMV disease and shorten the course of their 
disease. However, its use was avoided in our children with 
CMV disease because of the additive nephrotoxicity oftacroli-
mus and foscamet observed in our adult population. 
The experiences at several centers have suggested that the 
use of intravenous ganciclovir is effective prophylaxis against 
CMV in recipients of solid organs [31-33]. In our global expe-
rience (with adults and children) with intestinal transplantation, 
we have noted that the frequency of CMV disease with and 
without ganciclovir prophylaxis was similar. In this pediatric 
experience. it appears that ganciclovir prophylaxis alone may 
be more effective in preventing CMV disease than the exclusive 
use of oral acyclovir. 
Only 6 of 19 patients receiving ganciclovir prophylaxis de-
veloped disease /31.5%), compared with 4 of 7 patients (57%) 
who received prophylaxis with oral acyclovir alone. Although 
this increase was not significant. it is possible that more experi-
ence and multicenter trials may provide better insights into 
effective prophylaxis against CMV disease after intestinal 
transplantation. Similarly. recently presented data regarding the 
prolonged use of oral ganciclovir suggest the potential utility 
of this prophylactic strategy [34]. This approach (alone Or i 
combination with use of high-titer immunoglobulin) is wonh n 
of study in recipients of intestinal transplantation and maY 
result in decreased rates of CMV disease in this population. Y 
The most effective strategy in the prevention ofCMV disease 
is the transplantation of seronegative allografts into seronega. 
tive recipients (D-fR -). This was exemplified by OUr 15 
D-/R- patients who remained CMV-free. Because the donor 
organ is a common inoculation source in seronegative recipi. 
ents after transplantation, it has been reported that patients 
in the serological cohort D+ IR - are at the greatest risk for 
development of CMV disease after transplantation of an intes. 
tine [17] as well as other types of allografts [16]. However 
we found an equal frequency and rate of recurrence of diseas~ 
in each of the D+/R-, D+/R+, and D-/R+ groups. However, 
there was a trend toward more persistent CMV disease involv-
ing the allograft in D+/R- children. It is of interest that these 
persistent episodes were not always symptomatic, but they did 
take up to 7 months to resolve histologically. Children in this 
group were the only ones to have CMV disease of the native 
gastrointestinal tract (66% of patients). 
We did not find si~ificant differences in the survival rates 
of patients with and without CMV disease, nor did we find a 
difference in survival between patients with CMV disease and 
children belonging to the D-/R - subgroup. Likewise, there 
were no significant differences in patient or graft survival rates 
among different CMV-serological-status subgroups, including 
patients in the subgroup D + IR -. This contrasts with our pre-
viously reported combined experience with adults and children 
[17]. This is partially explained by the fact that there were no 
deaths directly attributable to CMV disease in this study. 
In summary, there appears to be less CMV-associated mOT-
bidity and mortality in children undergoing intestinal trans-
plantation than in adult intestinal-transplant recipients at our 
center. The high rates of morbidity and mortality previously 
reported with regard to our global experience with CMV dis-
ease following intestinal transplantation in adults and children 
had led us to recommend the use of CMV -negative donors for 
CMV -seronegative intestinal transplant recipients. 
This recommendation remains reasonable for recipients of 
isolated intestinal transplants in whom transplantation is not 
performed on an emergent basis. However, given the reason-
able outcome of D+/R - children reported in this study, for 
pediatric patients urgently awaiting composite intestinal allo-
grafts because of concomitant liver failure inducc;d by total 
parenteral nutrition, we recommend using CMV-positive do-
nors when seronegative donors are not available. 
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